PURA syndrome: clinical delineation and genotype-phenotype study in 32 individuals with review of published literature by Reijnders, Margot R. F. et al.
104 Reijnders MRF, et al. J Med Genet 2018;55:104–113. doi:10.1136/jmedgenet-2017-104946
Original article
PURA syndrome: clinical delineation and genotype-
phenotype study in 32 individuals with review of 
published literature
Margot r F reijnders,1 robert Janowski,2 Mohsan alvi,3 Jay e Self,4,5 ton J van essen,6 
Maaike Vreeburg,7 rob P W rouhl,8,9,10 Servi J c Stevens,7 alexander P a Stegmann,7 
Jolanda Schieving,11 rolph Pfundt,1 Katinke van Dijk,12 eric Smeets,7 
connie t r M Stumpel,7 levinus a Bok,13 Jan Maarten cobben,14 Marc engelen,15 
Sahar Mansour,16 Margo Whiteford,17 Kate e chandler,18 Sofia Douzgou,18 
nicola S cooper,19 ene-choo tan,20 roger Foo,21,22 angeline H M lai,23 Julia rankin,24 
andrew green,25 tuula lönnqvist,26 Pirjo isohanni,26,27 Shelley Williams,28 
ilene ruhoy,29 Karen S carvalho,30 James J Dowling,31 Dorit l lev,32 
Katalin Sterbova,33 Petra lassuthova,33 Jana neupauerová,33 Jeff l Waugh,34 
Sotirios Keros,35 Jill clayton-Smith,36 Sarah F Smithson,37 Han g Brunner,1,7 
ceciel van Hoeckel,38 Mel anderson,38 Virginia e clowes,39 Victoria Mok Siu,40 
the DDD study,41 Paulo Selber,42 richard J leventer,43 christoffer nellaker,44,45,46 
Dierk niessing,2,47 David Hunt,48,49 Diana Baralle48,49
Phenotypes
To cite: reijnders MrF, 
Janowski r, alvi M, et al. 
J Med Genet 
2018;55:104–113.
 ► additional material is 
published online only. to view 
please visit the journal online 
(http:// dx. doi. org/ 10. 1136/ 
jmedgenet- 2017- 104946).
For numbered affiliations see 
end of article.
Correspondence to
Margot r F reijnders, 
Department of Human genetics, 
radboud University Medical 
center, 6500 HB nijmegen, 
netherlands;  margot. reijnders@ 
radboudumc. nl and Dr Diana 
Baralle, Human genetic 
and genomics, University 
of Southampton, Human 
Development and Health, 
Duthie Building, Southampton 
general Hospital, tremona road, 
Southampton SO16 6YD, UK;  D. 
Baralle@ soton. ac. uk
DH and DB contributed equally.
received 27 July 2017
revised 29 august 2017
accepted 13 September 2017
Published Online First 
2 november 2017
AbsTrACT
background De novo mutations in PURA have 
recently been described to cause PUra syndrome, a 
neurodevelopmental disorder characterised by severe 
intellectual disability (iD), epilepsy, feeding difficulties 
and neonatal hypotonia.
Objectives to delineate the clinical spectrum of PUra 
syndrome and study genotype-phenotype correlations.
Methods Diagnostic or research-based exome or 
Sanger sequencing was performed in individuals with iD. 
We systematically collected clinical and mutation data on 
newly ascertained PUra syndrome individuals, evaluated 
data of previously reported individuals and performed 
a computational analysis of photographs. We classified 
mutations based on predicted effect using 3D in silico 
models of crystal structures of Drosophila-derived 
Pur-alpha homologues. Finally, we explored genotype-
phenotype correlations by analysis of both recurrent 
mutations as well as mutation classes.
results We report mutations in PURA (purine-rich 
element binding protein a) in 32 individuals, the largest 
cohort described so far. evaluation of clinical data, 
including 22 previously published cases, revealed that 
all have moderate to severe iD and neonatal-onset 
symptoms, including hypotonia (96%), respiratory 
problems (57%), feeding difficulties (77%), exaggerated 
startle response (44%), hypersomnolence (66%) and 
hypothermia (35%). epilepsy (54%) and gastrointestinal 
(69%), ophthalmological (51%) and endocrine problems 
(42%) were observed frequently. computational analysis 
of facial photographs showed subtle facial dysmorphism. 
no strong genotype-phenotype correlation was identified 
by subgrouping mutations into functional classes.
Conclusion We delineate the clinical spectrum of 
PUra syndrome with the identification of 32 additional 
individuals. the identification of one individual through 
targeted Sanger sequencing points towards the clinical 
recognisability of the syndrome. genotype-phenotype 
analysis showed no significant correlation between 
mutation classes and disease severity.
InTrOduCTIOn
Deletions in the 5q31.2q31.3 region have been 
reported to cause a syndrome comprising severe 
developmental delay, profound hypotonia, feeding 
difficulties, abnormal breathing pattern and 
seizures.1–5 Within this region, haploinsufficiency of 
the purine-rich element binding protein A (PURA) 
has been suggested as responsible for the observed 
neurodevelopmental features by narrowing the 
region of overlap to three genes.4 Further evidence 
for the essential role of PURA in development came 
from two articles describing 15 individuals with 
intellectual disability (ID) and de novo mutations in 
PURA.6 7 The pathogenicity of mutations in PURA 
was further supported by publication of a cohort 
of six additional individuals with ID and de novo 
mutations in PURA and two case reports.8–10
The functionality of PURA is dependent on three 
PUR motifs, PUR I, PUR II and PUR III.11 12 The 
ubiquitously expressed PURA protein, Pur-alpha, 
has multiple regulatory functions in processes 
such as DNA replication and transcription, mRNA 
transport and DNA repair.12 13 Several studies 
have shown that Pur-alpha has an important role 
in neuronal development and differentiation.14 In 
animal models, Pur-alpha is involved in postnatal 
brain development.15 16 The Pur-alpha deficient 
knockout mouse model has a severe neurological 
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phenotype, including tremor and spontaneous seizures.16 
Recently, heterozygous PURA knockout mice have been reported 
to develop gait abnormalities, hypotonia and memory deficits. 
Immunohistochemical assays displayed a reduced number of 
neurons in cerebellum and hippocampus of these animals, which 
is in line with their neurological, behavioural and cognitive 
phenotypes.17
Mental retardation, autosomal dominant type 
31[MIM616158], or ‘PURA syndrome’, the name of the 
syndrome adopted by the parents and clinical community alike, 
is phenotypically hallmarked by a wide spectrum of neurodevel-
opmental problems, including severe neurodevelopmental delay, 
epilepsy, abnormal movements, hypotonia and brain abnormali-
ties. Additionally, neonatal respiratory insufficiency and feeding 
difficulties have been reported. Outside of this core phenotype, 
a broad variability in clinical severity has been observed within 
PURA syndrome.6–9 Different types of mutations have been iden-
tified so far and mutations occur throughout the gene. It has 
been suggested that disruption of PUR repeat III possibly results 
in a more severe phenotype, but additional studies are needed to 
better understand the genotype-phenotype correlation of PURA 
mutations.7
We present 32 individuals with de novo mutations in PURA. 
With this large cohort, we delineate the clinical spectrum of 
PURA syndrome. Computational modelling shows that subtle 
overlapping facial dysmorphism is present. Additionally, we 
present an approach for genotype-phenotype analysis of iden-
tified mutations and associated phenotypes, revealing that 
observed phenotypic variability is probably not associated with 
type and localisation of mutations.
MeThOds
Identification of PurA syndrome individuals and collection of 
clinical and mutational data
Whole exome sequencing (WES) was performed in individuals 
with ID in either diagnostic (n=20) or research (n=10) settings 
(online supplementary methods). In one individual, targeted 
massively parallel sequencing (MPS) of a severe childhood 
epilepsy gene panel was used, and in a second individual, clin-
ically suspected to have PURA syndrome, PURA [NM_005859] 
was investigated with targeted Sanger sequencing. Parental 
samples were tested to assess de novo state. A questionnaire 
with clinical and mutational details was completed by clinicians. 
Written consent for publication of photographs was obtained 
from legal guardians.
evaluation of previously published cases
Twenty-two individuals with PURA mutations have been 
described in four different publications.6–9 We used the same 
questionnaire to collect clinical and mutation data from individ-
uals (n=22) reported in the literature.
Computational analysis of facial photographs
To visualise the characteristic facial features of PURA syndrome 
individuals, we generated a realistic, deidentified average based 
on 34 photographs of individuals (in this paper presented and 
previously published photographs) at different ages. A control 
average was created from 301 age-matched, healthy individ-
uals. We used a fully automated algorithm that (1) annotated a 
constellation of 68 facial landmark points on the face, (2) created 
an average face mesh and (3) warped faces of each individual 
onto the average face mesh. The face averaging algorithm was 
inspired by previous work18 19 and improved upon with better 
deidentification of individuals (online supplementary methods). 
Interpretation of the composite PURA face was performed by a 
panel of five independent dysmorphologists.
Functional assessment of PURA mutations in structural 
homology models
For homology modelling of mutations, the crystal structures 
of the N-terminal PUR domain (PDB-ID: 3K44) and of the 
C-terminal PUR domain (PDB-ID: 5FGO) from Drosophila mela-
nogaster were used as template. Homology structures of human 
PUR domains were calculated using the PHYRE2 program.20 In 
the case of the C-terminal PUR domain, the sequences of two 
repeat IIIs were merged into one peptide chain to allow for 
modelling of the entire domain. The human homology models 
showed high confidence scores and were used for in silico muta-
tional analyses using the program Coot.21 All mutations iden-
tified in our cohort and previously published cohorts6–9 were 
included. Variants in PURA reported in the Exome Aggregation 
Consortium (ExAC) database22 were included as controls. Dele-
tions, frameshift, non-sense and missense mutations were manu-
ally classified depending on the position, size and function of the 
affected amino acids. Point mutations were in silico introduced 
using the standard rotamer library of Coot and analysed for the 
appearance of steric clashes or repulsive forces of side chains. 
They were classified based on the orientation of mutated side 
chains and on our knowledge of functionally important surface 
regions. Figures were prepared using the program Pymol (www. 
pymol. org).
resulTs
Identification of 32 individuals
We report 32 individuals with mutations in PURA (figure 1). All, 
but two, were identified using WES in a diagnostic setting (indi-
viduals 1–10, 20–27, 30 and 32) or research setting (individuals 
12–19, 29 and 31). Individual 28 was identified using targeted 
MPS of a severe childhood epilepsy gene panel. Individual 11 
was clinically suspected to have PURA syndrome based on post-
term birth, severe neonatal hypotonia, hypersomnolence, exag-
gerated startle, persistent apnoeic episodes requiring continuous 
SpO2 monitoring and supplementary oxygen, and feeding diffi-
culties warranting nasogastric tube placement. Targeted Sanger 
sequencing revealed a PURA mutation. Mutations were de 
novo in 29 individuals. For the remaining three individuals, no 
parental blood was available for testing. None of the individuals 
had a second, likely pathogenic, genetic variant in WES data. All 
identified missense mutations localised in one of the PUR repeat 
sequences (figure 1).
Clinical delineation of 32 individuals
Clinical features observed in individuals reported in this 
study are summarised in table 1. Numbers and percentages of 
features were corrected for the number of individuals without 
available information on a specific feature. More extensive and 
detailed clinical information is available in online supplementary 
table 1.
Gestation and neonatal problems
More than half (56%) of individuals were born after >41 
weeks’ gestation. Induction of labour and/or caesarian 
section were reported in 14 individuals. In 55% (6/11), 
excessive hiccups were mentioned in utero. Neonatal prob-
lems were evident in all children immediately after birth. 
Hypotonia was present in all but one of the neonates, often 
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causing feeding difficulties (81%). Apnoeas and congenital 
hypoventilation were reported in 48% of the neonates. Both 
feeding and respiratory problems often required monitoring 
in hospital: in 20 neonates, tube feeding, oxygen supple-
mentation and/or mechanical ventilation were needed. 
Hypersomnolence (66%) and hypothermia (37%) were 
observed in a significant number of neonates. In about half 
of the neonates (58%) an exaggerated startle response was 
noted.
Development
All individuals with PURA mutations have moderate to severe 
ID with severe language and motor delay. Most individuals 
remain non-verbal (29/32, 91%), but many have better recep-
tive language than expressive language and can follow simple 
instructions. Severalnever achieved independent ambulation 
(10/24 with age >5 years, 42%). For those who did, the age 
of first steps ranged from 28 months to 7 years. Regression of 
achieved skills due to the onset of seizures has been reported 
in six individuals.
Neurological abnormalities
A variety of neurological problems were observed in individuals 
with PURA mutations. Hypotonia, often more prominent in the 
trunk, was present from birth. Spasticity of extremities at older 
age was reported in three individuals, and Babinski response 
was reported in another two. Gait, if achieved, was often 
unstable and broad based. Stereotypic hand movements, in 
some cases such as described for Rett syndrome [MIM312750], 
were observed in several individuals (36%). Six out of 30 
(20%) were mentioned to have a movement disorder, including 
dystonia, chorea-like movements, seizure-like movements with 
normal EEG and ataxic movements. Delayed myelination is the 
most frequently reported brain abnormality observed on MRI 
images (28%). Other, mostly a-specific, observed brain abnor-
malities (in 31% of individuals) include white matter abnor-
malities, prominent periventricular spaces, mild parenchymal 
atrophy, widening of lateral ventricles and underdeveloped 
rostrum of the corpus callosum. Peripheral neuropathy was 
measured in five individuals at young age (online supplemen-
tary table 1).
Figure 1 localisation of PURA mutations and subdivision in classes. Mutations of individuals identified in our cohort are marked in bold. (a) Homology 
models of n-terminal and c-terminal PUr domains (grey and blue, respectively) from human Pur-alpha. residues with single amino acid exchanges are 
depicted in red with side chains. (B) location of reported PURA frameshift and non-sense mutations. class a1 mutations are located in the n-terminal PUr 
domain that affect both n-terminal and c-terminal domains and class a2 mutations occur in the c-terminal domain, affecting only this domain and the 
c-terminus. (c) identified point mutations in one of the PUr domains, predicted to cause local folding defects. (D) Four mutations of amino acids located on 
the protein surface. three mutations are predicted to affect nucleic acid binding (class c) and one mutation (class D) likely affects a surface-exposed residue, 
which is not predicted to impair protein folding or nucleic acid binding. this mutation is possibly involved in not yet understood functions such as  
protein–protein interactions. (e) Deletion (red) caused by mutation p.(Met1?) (class e), which disrupts the start codon. the protein is likely expressed from the 
next in-frame start codon at amino acid 104, causing loss of a functional n-terminal PUr domain, but has an intact c-terminal PUr domain. (F) localisation 
of mutations reported in healthy controls in the exac database. all these mutations are predicted to have no effects on the folding and the function of the  
Pur-alpha protein. PUr, purine-rich element.
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Half of the individuals (50%) were diagnosed with epilepsy. For 
most of them, seizures started at the age of 2–4 years, but the age 
of onset ranged from 6 months to 15 years. Different seizure types 
were reported, including generalised tonic-clonic seizures, focal 
seizures, absence seizures, epileptic spasms, tonic seizures, drop 
attacks and over time, evolution to Lennox-Gastaut syndrome. The 
epilepsy is often refractory to medical treatment and some individ-
uals have never been seizure free. A longer follow-up period will be 
required to determine the true prevalence of epilepsy, how refrac-
tory it is and what treatments are most effective.
Ophthalmological abnormalities
Eye abnormalities and visual problems were described frequently 
in PURA syndrome individuals (40%). Strabismus (often 
oesotropia) was the most commonly reported finding along with 
strabismus-associated refractive errors (often hypermetropia). 
Cortical visual impairment was reported in three individuals; 
however, it is important to note that diagnostic criteria for 
this condition are highly variable. One individual was treated 
successfully for a congenital retinoblastoma. Nystagmus was also 
described in a small number of cases (4/29; 14%) but details of 
the phenotype are missing in reported cases.
Skeletal abnormalities
Progressive hip dysplasia and scoliosis were present in 
respectively 23% and 28% of the cases and could possibly be 
related to chronic truncal hypotonia (with or without abnor-
malities of limb tone), joint laxity and delayed or incomplete 
motor development. Surgical correction was required in five 
individuals in this cohort to date. The oldest individual was 
18 years at time of surgery. Longer follow-up might show a 
larger number of surgical interventions, since the majority 
of included individuals (27/32) had an age of examination 
below 18 years. Individuals showed a tendency to short 
Table 1 Percentage of clinical features reported in individuals in this article (n=32) and meta-analysis with previously published PURA individuals 
(n=22)6–9
Clinical feature
This article (n=max 32) literature (n=max 22)6–9 Total (n=max 54)
Percentage (%) number Percentage (%) number Percentage (%) number
Growth
  Short stature (≤2.5 SD) 19 5/27 14 3/22 16 8/49
Pregnancy/delivery
  Gestational age >41 weeks 56 18/32 60 3/5 57 21/37
Neonatal problems
  Hypotonia 97 31/32 94 15/16 96 46/48
  Feeding difficulties 81 25/31 73 16/22 77 41/53
  GORD 28 8/29 17 1/6 26 9/35
  Breathing problems 48 15/31 68 15/22 57 30/53
  Hypersomnolence 66 19/29 NR NR 66 19/29
  Hypothermia 37 10/27 25 1/4 35 11/31
  Excessive hiccups in utero 55 6/11 NR NR 55 6/11
Neurological abnormality
  Moderate to severe ID 100 32/32 100 22/22 100 54/54
  Hypotonia 97 31/32 80 4/5 95 35/37
  Stereotypic hand movements 36 8/22 NR NR 36 8/22
  Exaggerated startle response 58 11/19 27 4/15 44 15/34
  Epilepsy 50 16/32 59 13/22 54 29/54
  Delayed myelination 28 9/32 24 5/21 26 14/53
  Movement disorder 20 6/30 30 3/10 22 9/40
  Other brain abnormalities 31 10/32 29 6/21 30 16/53
Skeletal abnormality
  Scoliosis 28 9/32 18 2/11 26 11/43
  Hip dysplasia 23 7/31 0 0/11 17 7/42
  Hyperlaxity 43 9/21 9 1/11 31 10/32
Gastrointestinalabnormality
  Constipation 62 18/29 50 3/6 60 21/35
  Drooling 66 20/30 83 5/6 69 25/36
Respiratory abnormality 26 8/31 27 4/15 26 12/46
Cardiac abnormality 13 4/32 25 2/8 15 6/40
Urogenital abnormality 26 8/31 9 1/11 21 9/42
Ophthalmological abnormality 40 12/30 67 14/21 51 26/51
Endocrine abnormality
  Vitamin D deficiency 47 7/15 25 1/4 42 8/19
  Other 26 5/19 50 2/4 30 7/23
Skin abnormality
  Soft skin 46 6/13 NR NR 46 6/13
GORD, gastro-oesophageal reflux disease; ID, intellectual disability; max, maximum; NR, not reported; PURA, purine-rich element binding protein A.
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stature with five having a height ≤2.5 SD, and six others 
with a height between −2 and −2.5 SD. From the remaining 
16 individuals, only 2 had a height >0 SD. Low bone density 
(z-score −4; 57%) was identified in a single case. Pes planus 
was present in 11 individuals.
Gastrointestinal abnormalities
Due to severe hypotonia, swallowing problems and excessive 
drooling were observed in more than half of the individuals 
(66%). Constipation was often present (62%) and may be severe, 
requiring the use of laxatives from early age.
Endocrine abnormalities
A diverse range of endocrine problems were reported, with low 
vitamin D most commonly reported (47%), and less frequently 
observed abnormalities including aberrant sex hormone levels, 
abnormal cortisol response and aberrant thyroid hormone levels 
(26%) (online supplementary table 1). It is likely that these prob-
lems are more common than observed, since not all individuals 
have been tested for endocrine abnormalities.
Congenital structural malformations
Although not frequently reported, some individuals had congen-
ital malformations of the heart, urogenital and/or respiratory 
tract. Cardiac malformations included a ventricular septal defect 
in two individuals, and an aberrant left subclavian artery, pulmo-
nary stenosis and mild, spontaneously closed persistent ductus 
arteriosus each in one individual. Abnormalities of the urogen-
ital tract were described in five individuals: cryptorchidism in 
three, kidney stones in two, and congenital hydronephrosis with 
megaureter and urinary reflux each in one individual. Laryngeal 
cleft was reported in a single case.
Facial dysmorphisms
Photographs of 21 individuals are shown in figure 2. No striking 
similarities were observed, but a myopathic face, high anterior 
hairline, almond-shaped palpebral fissures and full cheeks were 
reported recurrently by clinicians. The presence of these features 
was confirmed by a panel of five independent dysmorphologists, 
all being asked to analyse photographs of PURA syndrome indi-
viduals from figure 2. They also mentioned eversion of lower 
lateral eyelids, prominent, well-defined philtrum and retrog-
nathia as features present in a subset of individuals.
expansion of the cohort with 22 previously published cases
We structurally analysed mutational and clinical data of 22 
previously published individuals.6–9 An overview of published 
mutations is present in figure 1 and summarised clinical infor-
mation is available in online supplementary table 2.
Recurrence of mutations
We found four recurrent mutations: p.(Lys97Glu) in individual 
20 and subject #4 in Lalani et al6; p.(Phe271del) in individual 
28 and subject #1 in Lalani et al6; p(Arg245Pro) in individuals 
1 and 15; p.(Phe233del) in individuals 4, 5 and 14, patient 4 
in Tanaka et al8 and patient 4 in Hunt et al.7 In addition, indi-
viduals 24 and 31 had two distinct mutations (c.153delA and 
c.155delG, respectively) that were both predicted to give rise to 
the same truncated protein product (p.(Leu54Cysfs*24)). There 
were six individuals between whom two distinct missense muta-
tions were identified at each of three different amino acid posi-
tions: p.(Leu100Arg) and p.(Leu100Pro) in individual 21 and 
subject #1 in Lalani et al6; p.(Ile206del) and p.(Ile206Phe) in 
individual 25 and patient 3 in Hunt et al7; p.(Val226Serfs*68) 
and p.(Val226Glyfs*67) in individuals 6 and 10.
Clinical evaluation
Clinical features such as neurodevelopmental delay, epilepsy, 
and brain and ophthalmological abnormalities have been 
reported in all previously published cohorts. But for the majority 
of features, no clinical information is available across all previ-
ously published cohorts. For example, hypersomnolence, 
Figure 2 Photographs of 21 individuals with PURA mutations. Shared facial dysmorphism includes high anterior hairline, almond-shaped palpebral 
fissures, full cheeks and hypotonic face. Strabismus is present in several of the PUra (purine-rich element binding protein a) individuals. additionally, 
independent dysmorphologists also observed eversion of lower lateral eyelids, prominent, well-defined philtrum and retrognathia in a subset of the 
individuals.
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stereotypic hand movements and excessive hiccups in utero have 
not been reported in literature before. Using the summarised 
clinical information (online supplementary table 2), we calcu-
lated the frequency of clinical features in all 54 individuals 
(table 1).
Computational analysis of facial dysmorphism
Since no striking overlap in facial dysmorphism was observed, 
but similarities between several individuals have been reported by 
clinicians, we performed an objective computational analysis in 
this paper presented and previously published photographs, 
and compared it to the average image based on healthy controls 
(figure 3). Ages at photographs ranged from 2 months to 19 
years. A panel of five independent dysmorphologists agreed that 
a myopathic face with typically open mouth appearance and full 
cheeks was visible on the computational modelled PURA face. 
Additionally, two dysmorphologists reported a slightly abnormal 
shape of the eyes as (1) shorter palpebral fissures and (2) ever-
sion of lower lateral eyelids. The high anterior hairline observed 
in a subset of individuals (6,7,8,9,11,13,14,16,17,28) was not 
visible on the computational model of the PURA face.
Modelling of all reported mutations into structural homology 
models of human Pur-alpha
Using the previously reported crystal structures of the N-ter-
minal and C-terminal PUR domains from the fruit fly D. mela-
nogaster11 12 as templates, we generated structural homology 
models for the corresponding domains of the human Pur-alpha 
paralogue. Based on these homology-modelled structures, all 46 
reported mutations were analysed and classified according to 
their predicted effects on domain folding and function.
The identified frameshift and non-sense mutations affecting 
the entire protein C-terminal to the site of mutation were 
defined as class A mutations. Depending on whether muta-
tions occurred in the N-terminal PUR domain and thus affect 
N-terminal and C-terminal PUR domains or in the C-terminal 
PUR only affecting this very domain plus C-terminus, we subclas-
sified them as A1 and A2 mutations, respectively (figure 1B). 
Mutations that were predicted to affect folding only locally, for 
instance, via amino acid exchange of a buried residue or short 
amino acid deletions in a folded region, were defined as class B 
mutations (figure 1C). Since the RNA and DNA-binding mode of 
Drosophila Pur-alpha has been structurally analysed,12 the human 
homology model could also be used to predict mutations that 
affect nucleic acid binding. Such mutations were found in four 
individuals and were defined as class C mutations (figure 1D). We 
also found one mutation likely affecting a surface-exposed residue 
that was neither predicted to impair protein folding nor nucleic 
acid binding. We suggest that this residue is involved in not yet 
understood functions such as protein–protein interactions and we 
defined this as class D mutation (figure 1D). Finally, we classified 
one mutation as class E: p.(Met1?), causing loss of the start codon. 
Translation is therefore likely to start at the next in-frame start 
codon, which is located at protein position 104. As a result, the 
protein will lack part of the N-terminal PUR domain, while it will 
have an intact C-terminal PUR domain (figure 1E). As control, we 
analysed variants reported by ExAC, a database containing vari-
ants of healthy controls (figure 1F). All of these variants resulted 
in single amino acid exchanges that are either located outside the 
globular domains or were exchanged against residues with similar 
side chain properties. Variant p.(Gln136Pro) is the only exception 
to this rule. It is located in the large loop region between repeats 
I and II and thus likely allows to compensate the changes in back-
bone conformation upon mutation into proline.
Genotype-phenotype analysis
Remarkable clinical variability has been observed within the 
total cohort of PURA syndrome individuals. To assess whether 
this variability could be explained by the type and/or localisa-
tion of the identified mutations, we compared (1) phenotypes 
of individuals with the same mutation and (2) phenotypes of 
individuals with a mutation of the same class.
Recurrent mutations
We observed four recurrent mutations and two mutations with 
a similar protein effect within the cohort, and compared their 
Figure 3 computational analysis of photographs of PUra (purine-rich element binding protein a) syndrome individuals. result of an objective 
computational analysis on photographs of 34 individuals with PURA mutations (ages at photographs ranging from 2 months to 19 years; right image) 
compared with the average image based on 301 age-matched, healthy controls (left image). the computational modelled PUra face showed a hypotonic 
face with typically open mouth appearance and full cheeks. additionally, two independent dysmorphologists reported a slightly abnormal shape of the eyes 
as (1) shorter palpebral fissures and (2) eversion of lower lateral eyelids. the high anterior hairline observed in a subset of individuals is not visible on this 
computational model of the PUra face.
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phenotypes. For all mutations, remarkable differences between indi-
viduals with the same mutation were present (table 2). For example, 
drug-resistant epilepsy was present in three out of five individuals 
with mutation p.(Phe233del) and a cardiac abnormality in two out 
of five individuals. The older of the two individuals without epilepsy 
could walk, in contrast to the three individuals with epilepsy, who 
were not able to walk or speak. For mutation p.(Leu54Cysfs*24), 
individuals had more features in common, such as epilepsy, scoliosis 
and short stature, but variation in ability to walk and heart abnor-
mality was also observed.
Comparison of mutation classes
We compared phenotypes of individuals subdivided by mutation 
class (online supplementary table 3). Overall, no significant differ-
ences in percentage of observed features between mutation classes 
were present. One exception is mutation p.(Glu283Argfs*45), 
which we classified as class D. This mutation affects only the very 
C-terminus (all three PUR domains are intact) and it is unlikely that 
this mutation interrupts protein folding or nucleic acid binding 
(online supplementary table 4; figure 1). Clinical features in this 
individual are less severe than observed in other individuals: the 
14-year-old girl could walk independently from the age of 2 years 
and could speak in sentences. Furthermore, no neonatal problems, 
hypotonia, epilepsy or brain abnormalities were present.7 The clin-
ical presentation of this girl is remarkably milder than other indi-
viduals, and could possibly be explained by the localisation of the 
mutation at the C-terminus.
dIsCussIOn
We report 32 individuals with PURA syndrome, the largest 
cohort so far. We systematically collected mutation and clinical 
data on these and previously published individuals. With infor-
mation on a total of 54 individuals, we were able to delineate the 
clinical spectrum of this recently discovered syndrome.
The detailed and systematic collection of phenotypic data 
allowed us to observe less frequently reported features related to 
PURA syndrome. Clinical problems such as excessive hiccups in 
utero (55% in our cohort), hypersomnolence (66% in our cohort), 
stereotypic hand movements (36% in our cohort), regression 
since onset of seizures (38% of individuals with epilepsy in our 
cohort), soft skin (46% in our cohort) and short stature (19% in 
our cohort) have not been reported before in published studies. 
Post-term birth (56% in our cohort), gastro-oesophageal reflux 
disease (28% in our cohort), hypothermia (37% in our cohort), 
hypotonia after the neonatal period (97% in our cohort), consti-
pation (62% in our cohort) and endocrine abnormalities (47% 
in our cohort) only have been mentioned in one other study. 
Similar to many other recently discovered novel syndromes for 
which only a small subset of individuals have been described 
initially, frequencies of features related to PURA syndrome were 
difficult to estimate based on reported numbers. By expanding 
the cohort, we were able to report a significant number of 
features not formally associated with PURA syndrome before. 
These features could be helpful for diagnosis and management 
of PURA syndrome individuals.
Table 2 Recurrent PURA mutations and phenotype of affected individuals
Mutation Individual/age reference Phenotype
p.(Leu54Cysfs*24) Individual 24
17 years
This article Hypotonia, feeding difficulties requiring TF, GORD, apnoeas, hypersomnolence, hypothermia, severe ID, no 
speech, walking at age 4 years, short stature (−5 SD), epilepsy, mild PDA, mild strabismus, scoliosis, hip 
dysplasia, small hands and feet
Individual 31
16 years
This article Hypotonia, feeding difficulties requiring TF, hypersomnolence, severe ID, no speech, not able to walk, short 
stature (−2.75 SD), epilepsy, scoliosis, epilepsy, long fingers
p.(Lys97Glu) Individual 20
2.5 years
This article Hypotonia, mild feeding difficulties, hypersomnolence, no speech, not able to walk, mild constipation, pes 
planus
Subject #4
21 months
Lalani et al6 Hypotonia, feeding difficulties, respiratory difficulties, seizures, ID, non-verbal, non-ambulatory, short stature 
(1%), strabismus, duplex left kidney, hydronephrosis
p.(Phe233del) Individual 4
14 years
This article Hypotonia, feeding difficulties, apnoeas, hypersomnolence, severe ID, no speech, able to walk, ASD, stereotypic 
hand movements, delayed myelination, swallow problems, severe hypermetropia, strabismus, low vitamin D, 
low ferritin, pes planus, abnormal peripheral nerve testing
Individual 5
19 years
This article Hypotonia, feeding difficulties, apnoeas, hypersomnolence, hypothermia, severe ID, no speech, not able to walk, 
stereotypic hand movements, epilepsy, nystagmus, delayed myelination, drooling, constipation, strabismus, CVI, 
scoliosis, hip dysplasia, low bone mineralisation, low vitamin D, anaemia, delayed puberty, small hands, pes 
planus
Individual 14
9 years
This article Hypotonia, severe ID, no speech, first steps age 7 years, epilepsy, delayed myelination, aberrant left subclavian 
artery, VSD, drooling, refraction abnormality, strabismus, low vitamin D, high cholesterol
Patient 4
6 months
Tanaka et al8 Hypotonia, CVI, periventricular leukomalacia
Patient 4
6 years, 9 months
Hunt et al7 Hypotonia, feeding difficulties requiring TF, apnoeas, hypothermia, severe ID, not able to walk, essentially non-
verbal, exaggerated startle response, dystonia, dyskinesia, epilepsy, CVI, delayed myelination, excessive extra-
axial fluid spaces, cerebral atrophy, hyperprolactinaemia, blunted cortisol stress response, low vitamin D
p.(Arg245Pro) Individual 1
19 years
This article Hypotonia, feeding difficulties, severe ID, no speech, not able to walk, autistic-like traits, chorea-like 
movements, Babinski response, delayed myelination, scoliosis, low vitamin D, hypogonadotropic hypogonadism
Individual 15
9 years
This article Hypotonia, feeding difficulties requiring TF, apnoeas, hypersomnolence, hypothermia, severe ID, no speech, first 
steps at age 4 years, epilepsy, drooling, constipation, pes planus
p.(Phe271del) Individual 28
11 months
This article Hypotonia, neonatal convulsions, moderate ID
Subject #1
6 months
Lalani et al6 Hypotonia, feeding difficulties, respiratory difficulties, seizures, ID, pedal oedema
ASD, autism spectrum disorder; CVI, cortical visual impairment; GORD, gastro-oesophageal reflux disease; ID, intellectual disability; PDA, persistent ductus arteriosus; TF, tube 
feeding; VSD, ventricular septum defects.
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The phenotype of PURA syndrome has been reported as diffi-
cult to recognise in daily clinical practice. Here, we show with the 
identification of one individual using targeted Sanger sequencing in 
a neonate, that it is possible to recognise PURA syndrome based 
on clinical features. Severe neonatal problems including hypotonia, 
respiratory and feeding difficulties, hypersomnolence and hypo-
thermia, in the majority combined with post-term birth, could point 
towards the early diagnosis of PURA syndrome. Although not a 
consistent feature, the presence of myoclonic jerks in a neonate with 
other features of PURA syndrome may be a useful feature to distin-
guish from Prader-Willi syndrome or peripheral neuromuscular 
disorders such as spinal muscular atrophy (SMA). Known syndromes 
such as congenital hypoventilation syndrome [MIM209880], 
Prader-Willi syndrome [MIM176270], Rett syndrome, Angelman 
syndrome [MIM160900], myotonic dystrophy [MIM160900] and 
SMA [MIM253300] have been tested often in PURA syndrome 
individuals. We recommend to considerPURA syndrome in the 
differential diagnosis of any child tested for one or more of the 
above syndromes, especially in the context of the aforementioned 
neonatal problems and/or unexplained developmental delay.
After diagnosis of PURA syndrome, careful management of 
existing medical problems and evaluation of health issues associ-
ated with PURA syndrome is essential. Our phenotypic overview 
shows that different organ systems could be affected. Therefore, we 
recommend routine care in a multidisciplinary team, with at least 
a (child) neurologist, ophthalmologist, orthopaedic surgeon and 
paediatrician for children aged below 18 years involved. Epilepsy, 
present in half of the cohort, is a major problem. Some individ-
uals have never been seizure free and regression of achieved devel-
opmental milestones since onset of seizures has been reported. In 
future, studies focusing on epilepsy will be important to optimise 
treatment of seizures related to PURA syndrome.
In general, individuals with epilepsy were more severely affected 
than individuals without epilepsy. However, this explained only 
partially the variation in developmental phenotypes observed 
between individuals. To assess whether the clinical variability could 
be related to the type and localisation of the identified mutations, 
we performed a genotype-phenotype study by analysing recurrent 
mutations and classifying mutations based on a homology model 
derived from a crystal structure of the Drosophila PUR-alpha homo-
logue. Interestingly, remarkable differences, such as the presence 
or absence of epilepsy or congenital malformations, were observed 
between individuals with the same mutation. For the remaining 
mutations, class D mutations with localisation at the very end 
of the C-terminus could possibly be correlated with a less severe 
phenotype. But for the other mutations, phenotypic variability and 
severity could not be related to the localisation and type of mutation. 
Based on these results, we suggest that other genetic and biological 
mechanisms contribute to the phenotypic variability. Further studies 
are needed to obtain insight into these underlying pathological 
mechanisms.
With the identification of 54 individuals within 2.5 years of the 
initial description of the condition, PURA syndrome appears to be a 
relatively frequent cause of ID. Previously, frequencies between 0.3% 
and 0.5% in neurodevelopmental cohorts have been reported.6–8 
Within our cohort, 10 individuals were identified in the diagnostic 
lab facility of the Radboudumc, Nijmegen. These were found in a 
total of 4700 individuals (~0.2%) with ID referred for WES. This 
frequency is probably an underestimate. It has been reported that 
PURA, a single-exon gene rich in guanine-cytosine content, could 
be challenging to capture, similar to the first exon of multiexonic 
genes.23 Furthermore, all 10 mutations have been identified after the 
introduction of PURA as an ID gene in diagnostic gene panels at the 
end of 2014, while WES had already been in use in the diagnostic 
lab of the Radboudumc from 2013. Therefore, to more accurately 
gauge the frequency within this population, a targeted re-evaluation 
of all available exome data would be necessary.
In conclusion, we present a detailed overview of the clinical spec-
trum of PURA syndrome and a computational modelled PURA face, 
which is essential for better recognition of this newly recognised 
disorder and surveillance and management of symptoms after 
initial diagnosis. Our suggested approach for genotype-phenotype 
analysis by modelling of identified PURA mutations into human 
homology models of experimentally determined crystal structures 
from Drosophila Pur-alpha, showed that clinical variation observed 
between individuals is probably not related to type and localisation 
of mutations, but should be sought in other genetic and biological 
mechanisms.
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